empagliflozin + torasemide

**Empagliflozin + torasemide** is an oral fixed-dose combination of two small-molecule agents: empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and torasemide, a loop diuretic. Empagliflozin lowers blood glucose by inhibiting SGLT2 in the renal proximal tubules, preventing glucose reabsorption and promoting glucosuria. Torasemide acts on the thick ascending limb of the loop of Henle to inhibit the Na⁺/K⁺/Cl⁻ cotransporter, promoting natriuresis and diuresis. The two drugs are used together for potential additive or synergistic diuretic, antihyperglycemic, and cardiovascular effects, primarily in patients with type 2 diabetes and cardiorenal comorbidities such as heart failure or chronic kidney disease. Combination therapy increases urinary glucose and sodium excretion and may enhance volume loss and neurohormonal adaptation compared to either drug alone[1][3][5][4][2].